Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in HBeAg-positive patients.

Chen Chien-HungCheng-Yuan PengYuan-Hung KuoTsung-Hui HuChao-Hung HungJing-Houng WangSheng-Nan Lu

Published in: The Journal of infectious diseases (2021)

TDF therapy, HBeAg loss without seroconversion during treatment and higher HBcrAg levels at EOT are significant predictors of HBV relapse in HBeAg-positive patients who discontinued entecavir or TDF.

Keyphrases

hepatitis b virus
liver failure
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
free survival
peritoneal dialysis
stem cells
patient reported
bone marrow
antiretroviral therapy